Rhythm Pharmaceuticals price to sales ratio RYTM

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: 25.6×
5-year median: 33.2×
Against its 5-year history: 3rd; percentile: 0 is its lowest day, 100 its highest
5-year range: 22.8× to 195×
Peer median: 8.5×

Rhythm Pharmaceuticals' price to sales ratio is 25.6× as of Oct 23, 2026.

That is below its 5-year median of 33.2×, lower than on 97% of days in the last 5 years.

Over that time it ranged from 22.8× in Apr 2025 to 195× in Mar 2022.

The median for 10 large drugmakers of a similar size is 8.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	25.6×	24.7×	40.2×
2025	42.1×	22.8×	48.3×
2024	30.4×	23.7×	48.8×
2023	43.8×	26.7×	116×
2022	98.5×	35.4×	195×

Against its peers

Companies in Drug Manufacturers - General nearest Rhythm Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
RYTMRhythm Pharmaceuticals	25.6×
LGNDLigand Pharmaceuticals	20.8×
KNSAKiniksa Pharmaceuticals International	7.1×
AMRXAmneal Pharmaceuticals	2.1×
ALKSAlkermes plc.	4.4×
TGTXTG Therapeutics	10.4×
PTGXProtagonist Therapeutics	31.8×
CORTCorcept Therapeutics	11.2×
INDVIndivior Pharmaceuticals	3.1×
ARQTArcutis Biotherapeutics	8.5×
LQDALiquidia	8.5×
Peer median	8.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Rhythm Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.